Sumitomo Pharma America, Inc., based in Fort Lee, NJ, is dedicated to improving global health by driving innovative treatments and technologies in critical areas such as psychiatry, neurology, oncology, urology, women's health, rare diseases, and cell gene therapy. Their diverse pipeline of preclinical and clinical programs aims to address high or unmet patient needs through a technology-driven approach.
As a U.S. subsidiary of Sumitomo Pharma Co., Ltd., SMPA embodies the promise of combining life sciences expertise with technology to enhance patient outcomes. With a focus on innovation and growth, they strive to accelerate drug discovery, development, and commercialization to meet the evolving health needs of humanity.
Generated from the website